anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncology and may be used in treatment patients with breast cancer. The method includes intravenous drip-feed of antitumor chemotherapeutic agents in autoplasma. At that the received autoplasma is exposed for 30 minutes with alternating magnetic field with parametres of 100 Hz, 50 mT. Then each antitumor chemotherapeutic agent in a single dose is mixed with autoplasma and is incubated at +37.0 C for not less than 30 minutes and is reirrigated intravenously by drop infusion. ^ EFFECT: invention enables to reduce size of the tumor and lymph nodes, transfer patients with locally advanced process from inoperable to operable condition, achieve remission due to concentration of chemical preparations of the highest possible effectiveness, and its delivery to the target-organs with the help of the plasma exposed to the magnetic field action. ^ 5 tbl, 4 dwg, 2 ex
Atopic dermatitis is recurring and chronic Allergic eczema which accompanies serious itching and xeroderma. Atopic dermatitis has special features such as increase of acidophil, high expression ratio of IgE in the blood. Recently, Atopic dermatitis is estimated to developing for 10 to 20 percent of the population in the world. However, there is no distinguished treatment to completely recover. Especially, most of diagnosis are made when the patients are younger than 5 years old. Moreover, 50 percent of them get diagnose Atopic dermatitis between 6 month and 24 month. According to the National epidemiological investigation conducted by the Korean Academy of Pediatric Allergy and Respiratory Disease, Outbreak ratio of Atopic dermatitis continually increase for the past decade. Accordingly, it has become a major social concern. It is really important for the patients to care and diagnose as soon as they find out symptoms of Atopic dermatitis. The reason is that 50 to 75 percent of the Atopic dermatitis patients are suffering from Allergies which cause asthma and rhinitis. Recently, It has been reported that Mesenchymal stem cells have special abilities to restrict the growth of lymphocyte non-specific and to restrict the activation of lymphocyte by the stimulus of mitogen or antigen. It is also reported that the restrict of lymphocyte by Mesenchymal stem cells does not need HLA-matching unlike the case of T-cell. It has been found that Mesenchymal stem cells' ability of autoimmune induction is weak because of low expression of antigen like HLA-DR. It is also discovered that Mesenchymal stem cells do not cause autoimmune side-effect even though we inject them in the body. When the body get infected by the pathogens, innate immune response operate as the primary defence mechanism. at this time, there are some receptors reacting first such as TLR(toll-like receptor) and NLR(nucleotide-binding oligomerization domain) which is located in the cytoplasm of a cell. It is reported that the activities of TLR which is expressed by Mesenchymal stem cells play an important roles about immunomodulatory ability of Mesenchymal stem cells. Furthermore, human Umbilical Cord Blood derived-Universal Stem Cells( hUCB-USCs) manifest TLR and NLR of Mesenchymal Stem cells at the same time. when those receptors become activation, it maximize ability of immunomodulatory. Therefore, hUCB-USCs can be utilized to cure intractable autoimmune disease like Atopic dermatitis. Further, It has huge possibility as cell therapy products for autoimmune disease.
The invention belongs to the technical field of traditional Chinese medicine beauty, and discloses a pure natural facial mask for whitening, tendering skin, removing spots and acne and a preparation method thereof; grinding 1g-5g of fructus Hippophae into fine powder with particle size of 50 μm-70 μm. Grinding 1g-5g Poria powder and 1g-4g radix Puerariae powder into 50 μm-70 μm fine powder. Mixing the ground sea-buckthorn powder and poria cocos powder with 6g-15g of honey, and fully stirring to form paste. Adding the ground radix Puerariae powder into the paste, and stirring to mix the radix Puerariae powder uniformly. The sea buckthorn powder used by the invention can be quickly absorbed by the skin, inhibits infection and flooding of propionibacterium acnes, repairs the damaged skin and recovers the normal renewal and circulation system of the skin; the radix Puerariae, Poria and Mel can nourish skin, lighten pigment, and also has effects of resisting aging, resisting wrinkle, and removing acne mark. The skin whitening cream has the advantages of simple formula and no side effect, can deeply whiten and treat the skin, ensures that people are full of love and confidence in life and work, and improves the happiness.
The investigators systematically reviewed the medical records of patients with a diagnosis of genetically confirmed FPLD at Reunion University Hospital (La Réunion, France) from 2006 (beginning of the screening for lipodystrophy) to 2020. Due to the high prevalence of lipodystrophy in our island and to follow the recommendations in follow up, a specific check-up is organized in our centre since 2016. For this study the investigators collected the data from patients who carried the same LMNA 'Reunionese' mutation: p.T655fsX49 and who benefited a complete check-up in our centre since 2016. Between 2006 and 2020, 97 patients were diagnosed with FPLD at Reunion University Hospital. Three different mutations were diagnosed: 85 subjects carried the 'Reunionese' mutation LMNA p.T655fsX49 (70 heterozygous and 15 homozygous), 8 carried the mutation LMNA p.R582H and 3 subjects carried a mutation of PPARγ. Among the carrier of the mutation LMNA p.T655fsX49, 70 subjects benefit a recent follow up with complete examination (61 heterozygous (HTZ) and 9 homozygous (HMZ)) and 4 deceased (all carrier of the homozygous form).
The single arm design assessing progression-free survival at 6 months (PFS-6) in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
The present invention provides an externally applied preparation for treating pedo-urticaria. The present invention is prepared from Chinese medicines, such as phellodendron bark, atractylodes rhizome, flavescent sophora root, mint, angelica, etc. and is mainly used for clearing heat, drying damp, killing insects, cooling, alleviating itching, nourishing the blood and the skin and improving affected region symptoms. The present invention has the advantages of scientific and reasonable prescription, high stability and small stimulation to the skin. According to the degree of state of diseases, the present invention can be prepared into washing liquid of which the concentration is 0.5% so that the patients can be treated during bathing; besides, the raw liquid of the present invention can be directly applied to affected regions. The present invention has the advantages of safe medication and economization and overcomes the defect of large toxic and side effect existing in western medicines; the present invention can not only clean the skin, suppress and kill bacteria and sofen epithelium but also is beneficial to the penetration of active ingredients into the skin to act; the present invention can shorten medicinal time of taking effect, and obviously eliminates rashes and raises the cure rate. Besides, the present invention is an ideal externally applied medicine for treating Kunming rashes.
This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.
Interferons are the first line of defense against viral infections and administration of interferons as biotherapeutics has been demonstrated to be effective in controlling several viral infections. Here we report for the first time the identification and characterization of a member of the bovine type III IFN family, boIFN-λ3. We have expressed boIFN-λ3 using a recombinant replication defective human adenovirus type 5 (Ad5) and demonstrated antiviral activity against foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) in bovine cells in vitro. Furthermore, we have tested the efficacy of boIFN-λ3 against FMDV in vivo by inoculation of cattle with Ad5-boIFN-λ3 followed by intradermolingual or aerosol virus challenge. Our results demonstrate that the type III IFN family is conserved in bovines and that treatment of cattle with boIFN-λ3 alone or in combination with IFN-α is able to confer delayed and reduced severity of FMD. Furthermore inoculation with Ad5-boIFN-λ3 alone conferred full protection against aerosol challenge for at least 7 days after administration suggesting that type III IFN used in combination with FMD vaccines could fill one of the current gaps in emergency vaccination against FMDV.
If you are breast feeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breast feeding. You should use another method of contraception since breast feeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breast feed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely.

3\. Laboratory Tests

If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills.

4\. Drug Interactions

Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include rifampin; drugs used for epilepsy such as barbiturates (for example, phenobarbital), carbamazepine, and phenytoin (Dilantin® is one brand of this drug); troglitazone; phenylbutazone; and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective.

Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophylline. You should tell your doctor if you are taking any of these medications.

5\. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.
The present invention relates to compositions and methods for inhibiting the aging of amino-containing amino acid, peptides, proteins and biomolecules.  Accordingly, a composition is disclosed which comprises an agent or compound capable of reacting with the glycosyl-amino moiety of the early glycosylation product (also known as the Amadori product or the Heyns product) formed by the reaction of glucose, or other reactive sugars, with an amino-containing peptide, protein or biomolecule, thus stabilizing this early glycosylation product, and preventing its further reaction to form open-chain, carbonyl-containing advanced glycosylation end products. Suitable agents may contain a reactive aldehyde group. A preferred agent is acetaldehyde. The method comprises contacting the target biomolecule with the composition. The compounds so obtained are represented by formulae (VI) and (VIII) wherein R is the residue of an amino-containing biomolecule such as a peptide and CH2R' is the residue of the reactive aldhehyde group. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
PURPOSE: Minimally invasive glaucoma surgery is safer and effective surgical modality for patients with glaucoma. To compare the effect of axial length (AL) on the surgical outcomes of combined cataract surgery and ab interno trabeculotomy (phaco-LOT), a retrospective, non-randomized comparative study was performed.
METHODS: In total, 458 eyes of 458 open-angle glaucoma patients who underwent phaco-LOT and were followed-up without any intervention for at least 6 months were enrolled. All were divided into a long-AL group (AL ≥ 26.0 mm, 123 eyes) and a not-long-AL group (AL < 26.0 mm, 335 eyes). The principal outcomes were the changes in intraocular pressure (IOP) and medication scores. We also sought a correlation between postoperative IOP spike and hyphema.
RESULTS: Significant postoperative reductions in IOP and medication scores were apparent in all subjects. The IOP reductions were significant at all timepoints in the not-long-AL group, but not until 1 month postoperatively in the long-AL group, and the IOP change was significantly lower in the long-AL group from postoperative day 1 to 3 months. On subanalysis of subjects by age, the microhook used, the pre-operative IOP, and the medication score, a significantly higher incidence of IOP spike was observed in the long-AL group in weeks 1 and 2 (both p < 0.05), but this did not correlate with hyphema status, implying that a different mechanism was in play.
CONCLUSION: Phaco-LOT was effective regardless of AL, but the postoperative IOP decrease was lower and the early postoperative incidence of IOP spike was higher in long-AL eyes.
BACKGROUND AND OBJECTIVE: Genetic polymorphism studies in families and twins indicated the heritability of depression. However, the association between genes with genetic polymorphism and depression provides various findings and remains unclear. Therefore, we conducted a systematic review and meta-analysis to determine the genes with their polymorphism associated with the symptomatic depression known as major depressive disorder (MDD).
MATERIALS AND METHODS: PubMed and Scopus were searched for relevant studies published before May 22, 2023 (1968-2023), and 62 were selected for this review. The study's bias risk was investigated using the Newcastle-Ottawa scale. Gene functional enrichment analysis was investigated for molecular function (MF) and biological process (BP) and pathways. A meta-analysis of the studied genes that were replicative in the same single nucleotide polymorphism was conducted using a random-effect model.
RESULTS: The 49 genes involved in MDD were studied and engaged in several pathways, such as tryptophan metabolism or dopaminergic and serotonergic synapses. Based on gene overlapping in MF and BP, 13 genes with polymorphisms were identified as related to MDD. Most of them were only studied once. Solute carrier family 6 member 4 (SLC6A4) overlapping between MF and BP and brain-derived neurotrophic factor (BDNF) as unique to BP were replicative studied and used in the meta-analysis. The polymorphism of SLC6A4 SS and LS genotypes increased the occurrence of MDD development but not significantly [odd ratio (OR) = 1.39; 95% confidence interval (CI) = 0.87-2.22; P = 0.16 and OR = 1.13; 95% CI = 0.84-1.53; P = 0.42, respectively]. A similar result was observed for BDNF rs6265 GG (OR = 1.26; 95% CI = 0.78-2.06; P = 0.35) and BDNF rs6265 AA genotypes (OR = 1.12; 95% CI = 0.77-1.64; P = 0.56). These studies indicated low bias and significant heterogeneity.
CONCLUSION: At least 13 studied genes with polymorphisms were involved in MDD development according to MF and BP, but not significantly. These results suggest that MDD development risk factors might require genetic and other factors for interaction and induction.
The intervention arm will involve participants, divided into four subgroups, taking part in field trips for visual and auditory birdwatching. These trips will take place every 15 days over three sessions, guided by an expert in the subject. Students will be provided with binoculars and guidance on the use of apps to identify observed birds. Additionally, WhatsApp groups will be created for each subgroup, where videos and audios of birds will be shared, along with weekly challenges to reinforce exposure to the intervention. The outings will take place in natural environments such as coffee farms and forests near Bucaramanga.
A ketogenic diet (KD) can induce weight loss and improve glycemic regulation, potentially reducing the risk of type 2 diabetes development. To elucidate the underlying mechanisms behind these beneficial effects of a KD, we investigated the impact of a KD on organ-specific insulin sensitivity (IS) in skeletal muscle, liver, and adipose tissue. We hypothesized that a KD would increase IS in skeletal muscle. The study included 11 individuals with obesity who underwent a randomized, crossover trial with two 3-week interventions: 1) a KD and 2) a standard diet. Skeletal muscle IS was quantified as the increase in glucose disposal during a hyperinsulinemic-euglycemic clamp (HEC). Hepatic IS and adipose tissue IS were quantified as the relative suppression of endogenous glucose production (EGP) and the relative suppression of palmitate flux during the HEC. The KD led to a 2.2-kg weight loss and increased insulin-stimulated glucose disposal, whereas the relative suppression of EGP during the HEC was similar. In addition, the KD decreased insulin-mediated suppression of lipolysis. In conclusion, a KD increased skeletal muscle IS in individuals with obesity.
A system for self-fulfillment of an alimentary instruction set based on vibrant constitutional guidance using artificial intelligence. The system includes a computing device designed and configured to receive training data. The computing device is further configured to record at least a biological extraction from a user and generate a diagnostic output. The computing device is further configured to generate a self-fulfillment instruction set utilizing the diagnostic output. The computing device is further configured to receive a user entry containing a completed alimentary self-fulfillment action. The computing device is further configured to update the self-fulfillment instruction set as a function of an alimentary self-fulfillment action.
BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) have dramatically altered obesity treatment. Media reports suggest that GLP-1 RAs users often report feeling judged for taking a "shortcut" to lose weight, which may be related to negative stereotypes toward people with larger bodies. Media reports also describe negative attitudes about lean people who take GLP-1 RAs to enhance their appearance. The present research used a 2 × 2 experimental design to test the effects of GLP-1 RA use and body size on attitudes and egocentric impressions.
SUBJECTS/METHODS: A sample of 357 U.S. adults (Mage = 37.8, SD = 13) were randomly assigned to read about a woman, who either was lean or had obesity, and who lost 15% of her body weight either with diet/exercise or a GLP-1 RA. Participants answered questions measuring endorsement of negative weight-related stereotypes and egocentric attitudes toward the woman, as well as beliefs that she took a shortcut to lose weight and beliefs that biogenetic factors caused her baseline weight.
RESULTS: Negative evaluations and egocentric impressions were stronger toward a woman who lost weight with a GLP-1 RA compared to diet/exercise. Losing weight with a GLP-1 RA led to stronger negative evaluations through higher weight loss shortcut beliefs irrespective of body size. Losing weight with a GLP-1 RA also led to higher egocentric impressions through higher shortcut beliefs, and this effect was stronger for a lean woman. Finally, losing weight with a GLP-1 RA led to more negative evaluations through stronger endorsement of biogenetic causal beliefs for a lean woman only.
CONCLUSIONS: This timely study provides evidence that people with larger and smaller bodies alike are at-risk for being judged for using GLP-1 RAs due to beliefs that these medications are a shortcut. Findings also demonstrate novel reactions related to egotism when weight loss is achieved with pharmacological interventions. PRE-REGISTRATION AND DATA: osf.io/xme4w.
The present invention relates to an infatmul containing docetaxel and its preparation method. Said preparation can be directly used for intravenous injection. At the same time of that it is used as medicine for curing tumor disease said preparation also can provide nutrients for patient. The weight volume concentration range of docetaxel contained by said preparation is 0.1-1.0 mg/ml, and its specification is that 1-500 mg of active component docetaxel is contained. Said infatmul composition includes docetaxel, vegetable oil, phospholipids and injection water, at the same time the components of glycerin and group emulsion, etc. can be added, in which the optimum group emulsion is poloxamer 188. Besides, said invention also provides the concrete steps of its preparation method and its application in preparation of medicine for resisting tumor.
The ePartogram is an electronic version of the WHO Partograph and is developed by Jhpiego. Seventy-eight clinical rules, programmed into the ePartogram, are based on global guidelines in the WHO manual "Managing complications in pregnancy and childbirth: a guide for midwives and doctors" and the expert opinion of Jhpiego physicians and nurse-midwives. The rules underwent a validation process by 65 expert skilled birth attendants (SBAs) (working in maternity wards of health facilities) from a variety of geographic and clinical settings affiliated with Jhpiego. In the ePartogram application ("app") that is put on an Android tablet computer, the clinical rules trigger "reminders" to SBAs to take a routine clinical measurement, such as fetal heart rate (every 30 minutes) or maternal temperature (every 2 hours). The rules also trigger "low-level" alarms indicating a measurement that falls in the abnormal range that could be cause for concern (i.e. meconium-stained liquor), and "high-level" alarms that could indicate need for immediate action (i.e. maternal systolic blood pressure ≥160 mm Hg).

Litwin et al. reported on the feasibility and acceptability of use of an electronic partogram in Zanzibar and concluded that health workers felt the ePartogram improved timeliness of care and supported decision making. Health workers quickly became competent and confident in using the tablet device and ePartogram application. This study in Kenya has an objective to evaluate whether providers' use of the ePartogram improves labor outcomes and labor management in health facilities. The study design is a quasi-experimental design evaluation comparing data collected at 6 intervention sites and 6 comparison sites with similar facility characteristics and in two regions of Kenya.